AstraZeneca PLC (AZN) on Decifer

Decifer ranks AZN number 228 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 9% a year and profits grew 45% over the past year.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Profits grew 45% with revenue up about 9%, but no stated worldview role and momentum of 4 out of 35 keep it in the middle.

The current read

The evidence on AZN lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: AstraZeneca PLC operates in drug manufacturers - general. That places it inside the Healthcare, Biotech & Devices story.

Read the full AZN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.